{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:27:41Z","timestamp":1746332861975},"reference-count":35,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["IDDT"],"published-print":{"date-parts":[[2019,2,4]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Highly Active Antiretroviral Therapy (HAART) has been implicated in renal dysfunction with hypophosphataemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>We prospectively evaluated renal phosphate excretion during HAART use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method:<\/jats:title><jats:p>Newly diagnosed human immunodeficiency virus (HIV)-infected individuals were treated with Tenofovir disoproxil fumarate\/Emtricitabine\/Efavirenz (TDF\/FTC\/EFV), n=33; Zidovudine\/Lamivudine\/Nevirapine (ZDV\/3TC\/NVP), n=53; and Zidovudine\/Lamivudine\/Efavirenz (ZDV\/3TC\/EFV), n=16. Creatinine and phosphate were assayed in blood and urine simultaneously at baseline, 1, 3, 6 and 9 months. Glomerular filtration rate (eGFR), fractional phosphate excretion and reabsorption (FEPi % and TRP), and the ratio of tubular maximum reabsorption of phosphate (TmP) to GFR (TmP\/GFR) were estimated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>At baseline, eGFR showed moderate chronic kidney disease (mean: 35.50 \u00b1 2.02, 33.14 \u00b1 1.63, and 39.97\u00b11.84 ml\/min\/1.73m2 in the 3 groups respectively); 54 (52.9%) patients had hyperphosphataemia (1.4mmo\/L); 43 (42.2%) had normophosphataemia (0.6-1.4mmol\/L); 5 (4.9%) had hypophosphataemia (&lt;0.6mmol\/L). eGFR improved significantly from 1 month (\u226560, 58.65 \u00b1 1.11, and 51.76 \u00b11.59 ml\/min\/1.73m2; p=0.04, &lt;0.001, 0.67 respectively), with a relapse at 9 months in TDFtreated subjects (50.10 \u00b1 1.89 ml\/min\/1.73m2). TDF\/FTC\/EFV resulted in&lt; significantly greater reduction in plasma phosphate than ZDV\/3TC\/NVP (p=0.031), but not significantly different from ZDV\/3TC\/EFV (p=0.968). Similarly, ZDV\/3TC\/EFV resulted in significantly greater reduction in plasma phosphate than ZDV\/3TC\/NVP (p=0.036).<\/jats:p><\/jats:sec><jats:sec><jats:title \/><jats:p>FEP% progressively increased with HAART duration, more in TDF-treated and ZDV\/3TC\/EFV-treated groups than ZDV\/3TC\/NVP (p=0.014); TRP was elevated (&lt;0.86), implying non-maximal phosphate reabsorption. TmP\/GFR values were elevated, (&lt;1.35mmol\/l).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>HIV causes kidney dysfunction with reduced phosphate excretion resulting in hyperphosphataemia but HAART improves renal function. Prolonged use of TDF can cause renal toxicity with hypophosphataemia as fractional excretion progressively increased with duration of therapy unlike ZDV\/3TC\/NVP. The use of different third agents (either NVP or EFV) in zidovudine-based therapy results in significantly different plasma phosphate levels; ZDV\/3TC\/EFV, like TDF\/FTC\/EFV, resulted in significantly greater decline in plasma phosphate than ZDV\/3TC\/NVP. Thus, Evafirenz (EVF) may have similar or synergistic adverse effects with tenofovir disoproxil fumarate (TDF).<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871526518666180720115240","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T11:47:22Z","timestamp":1532087242000},"page":"88-100","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Highly Active Antiretroviral Therapy on Renal Function and Renal Phosphate Handling in African Adults with Advanced HIV and CKD"],"prefix":"10.2174","volume":"19","author":[{"given":"Tewogbade A.","family":"Adedeji","sequence":"first","affiliation":[{"name":"Department of Chemical Pathology, Obafemi Awolowo University, Ile-Ife, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeon A.","family":"Adebisi","sequence":"additional","affiliation":[{"name":"Department of Chemical Pathology, Benue State University, Makurdi, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nife O.","family":"Adedeji","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sikiru A.","family":"Biliaminu","sequence":"additional","affiliation":[{"name":"Department of Chemical Pathology, University of Ilorin, Ilorin, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy O.","family":"Olanrewaju","sequence":"additional","affiliation":[{"name":"Department of Medicine (Renal Unit), University of Ilorin, Ilorin, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"153","author":"Walmsley R.N.","year":"1984","unstructured":"Walmsley RN, and Guerin MD. Renal Disease.","journal-title":"Disorders of fluid and electrolyte balance"},{"key":"ref=2","first-page":"1905","author":"Endres D.B.","year":"1999","unstructured":"Endres DB, Rude RK. Mineral and bone metabolism.","journal-title":"Teitz textbook of clinical chemistry"},{"key":"ref=3","unstructured":""},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1046\/j.1523-1755.1999.00748.x","volume":"56","author":"Klotman P.E.","year":"1999","unstructured":"Klotman PE. HIV-associated nephropathy.","journal-title":"Kidney Int"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"Gutierrez O.","year":"2005","unstructured":"Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, J&#xFC;ppner H, Wolf M. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.","journal-title":"J Am Soc Nephrol"},{"key":"ref=6","first-page":"569","volume":"147","author":"Yu G.C.","year":"1987","unstructured":"Yu GC, Lee DBN. Clinical disorders of phosphorus metabolism.","journal-title":"West J Med"},{"key":"ref=7","first-page":"619","author":"Knochel J.P.","year":"1986","unstructured":"Knochel JP, Jacobson HR. Renal handling of phosphorus in health and disease.","journal-title":"The Kidney"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/000456329803500203","volume":"35","author":"Payne R.B.","year":"1998","unstructured":"Payne RB. Renal tubular reabsorption of phosphate (TmP\/GFR): indications and interpretation.","journal-title":"Ann Clin Biochem"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/ndt\/gfh658","volume":"20","author":"Izzedine H.","year":"2005","unstructured":"Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, Cheng A, Deray G. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.","journal-title":"Nephrol Dial Transplant"},{"key":"ref=10","first-page":"301","volume":"38","author":"Day S.L.","year":"2005","unstructured":"Day SL, Leake Date HA, Bannister A, Hankins M, Fisher M. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=11","unstructured":""},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2010.1004","volume":"304","author":"Thompson M.A.","year":"2010","unstructured":"Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, G&#xFC;nthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.","journal-title":"JAMA"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1258\/0004563001901371","volume":"37","author":"Barth J.H.","year":"2000","unstructured":"Barth JH, Jones RG, Payne RB. Calculation of renal tubular reabsorption of phosphate: the algorithm performs better than the nomogram.","journal-title":"Ann Clin Biochem"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(75)92736-1","volume":"2","author":"Walton R.J.","year":"1975","unstructured":"Walton RJ, Bijvoet OLM. Nomogram for derivation of renal threshold phosphate concentration.","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"19564","DOI":"10.7448\/IAS.17.4.19564","volume":"17","author":"Pitisci L.","year":"2014","unstructured":"Pitisci L, Demeester R, Legrand JC. Prevalence and European AIDS Clinical Society (EACS) criteria evaluation for proximal renal tubular dysfunction diagnosis in patients under antiretroviral therapy in routine setting.","journal-title":"J Int AIDS Soc"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","volume":"57","author":"Hall A.M.","year":"2011","unstructured":"Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.","journal-title":"Am J Kidney Dis"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/sj.ki.5000351","volume":"69","author":"Gerntholtz T.E.","year":"2006","unstructured":"Gerntholtz TE, Goetsch SJW, Katz I. HIV-related nephropathy: a South African perspective.","journal-title":"Kidney Int"},{"key":"ref=18","first-page":"125","volume":"2","author":"Cohen A.H.","year":"1989","unstructured":"Cohen AH, Sun NCJ, Shapsak P. Demonstration of HIV in renal epithelium in HIV-associated nephropathy.","journal-title":"Mod Pathol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1681\/ASN.V11112079","volume":"11","author":"Bruggeman L.A.","year":"2000","unstructured":"Bruggeman LA, Ross MD, Tanji N, Cara A, Dikman S, Gordon RE, Burns GC, D&#x2019;Agati VD, Winston JA, Klotman ME, Klotman PE. Renal epithelium is a previously unrecognized site of HIV-1 infection.","journal-title":"J Am Soc Nephrol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/ki.1993.189","volume":"43","author":"Kimmel P.L.","year":"1993","unstructured":"Kimmel PL, Ferreira-Centeno A, Farkas-Szallasi T, Abraham AA, Garrett CT. Viral DNA in microdissected renal biopsy tissue from HIV infected patients with nephrotic syndrome.","journal-title":"Kidney Int"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-101-4-429","volume":"101","author":"Pardo V.","year":"1984","unstructured":"Pardo V, Aldana M, Colton RM, Fischl MA, Jaffe D, Moskowitz L, Hensley GT, Bourgoignie JJ. Glomerular lesions in the acquired immunodeficiency syndrome.","journal-title":"Ann Intern Med"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM198403153101101","volume":"310","author":"Rao T.K.","year":"1984","unstructured":"Rao TK, Filippone EJ, Nicastri AD, Landesman SH, Frank E, Chen CK, Friedman EA. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome.","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJM200106283442604","volume":"344","author":"Winston J.A.","year":"2001","unstructured":"Winston JA, Bruggeman LA, Ross MD, Jacobson J, Ross L, D&#x2019;Agati VD, Klotman PE, Klotman ME. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection.","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1046\/j.1523-1755.2003.00901.x","volume":"63","author":"Weiner N.J.","year":"2003","unstructured":"Weiner NJ, Goodman JW, Kimmel PL. The HIV-associated renal diseases: current insight into pathogenesis and treatment.","journal-title":"Kidney Int"},{"key":"ref=25","first-page":"S43","author":"Kopp J.B.","year":"2003","unstructured":"Kopp JB, Winkler C. HIV-associated nephropathy in African Americans.","journal-title":"Kidney Int Suppl"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1097\/01.ASN.0000083392.11042.14","volume":"14","author":"Stehman-Breen C.O.","year":"2003","unstructured":"Stehman-Breen CO, Gillen D, Steffes M, Jacobs DR, Lewis CE, Kiefe CI, Siscovick D. Racial differences in early-onset renal disease among young adults: the coronary artery risk development in young adults (CARDIA) study.","journal-title":"J Am Soc Nephrol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/314033","volume":"31","author":"Chemlal K.","year":"2000","unstructured":"Chemlal K, Nochy D, Kenouch S, Joly V, Carbon C. Dramatic improvement of renal dysfunction in a human immunodeficiency virus-infected woman treated with highly active antiretroviral therapy.","journal-title":"Clin Infect Dis"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/428840","volume":"40","author":"Gallant J.E.","year":"2005","unstructured":"Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.","journal-title":"Clin Infect Dis"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00002030-200501030-00012","volume":"19","author":"Mauss S.","year":"2005","unstructured":"Mauss S, Berger F, Schmutz G, Stefan F. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.","journal-title":"AIDS"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/ckj\/sfv041","volume":"8","author":"Waheed S.","year":"2015","unstructured":"Waheed S, Attia D, Estrella MM, Zafar Y, Atta MG, Lucas GM, Fine DM. Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series.","journal-title":"Clin Kidney J"},{"key":"ref=31","first-page":"1001","volume":"27","author":"Wanner D.P.","year":"2009","unstructured":"Wanner DP, Tyndall A, Walker UA. Tenofovir-induced osteomalacia.","journal-title":"Clin Exp Rheumatol"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.trsl.2012.01.014","volume":"159","author":"Slocum J.L.","year":"2012","unstructured":"Slocum JL, Heung M, Pennathur S. Marking renal injury: can we move beyond serum creatinine?","journal-title":"Transl Res"},{"key":"ref=33","unstructured":""},{"key":"ref=34","unstructured":""},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc0800696","volume":"359","author":"Cirillo M.","year":"2008","unstructured":"Cirillo M, Ciacci C, De Santo NG. Age, renal tubular phosphate reabsorption, and serum phosphate levels in adults.","journal-title":"N Engl J Med"}],"container-title":["Infectious Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/163942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T23:44:23Z","timestamp":1661643863000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/163942\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871526518666180720115240","relation":{},"ISSN":["1871-5265"],"issn-type":[{"value":"1871-5265","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}